Irving J, Matheson E, Minto L, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124(23):3420-3430.

On page 3420 in the 27 November 2014 issue, the affiliation of the 11th author, Jana Hof, is incomplete. The second and third affiliations, which were not listed, are “German Cancer Consortium (DKTK), Berlin, Germany, and German Cancer Research Center (DKFZ), Heidelberg, Germany.” The byline and affiliations should have read as shown below. The errors have been corrected in the online version, which now differs from the print version.

Julie Irving,¹ Elizabeth Matheson,¹ Lynne Minto,¹ Helen Blair,¹ Marian Case,¹ Christina Halsey,² Isabella Swidenbank,³ Frida Ponthan,¹ Renate Kirschner-Schwabe,^4,5 Stefanie Groeneveld-Krentz,⁴ Jana Hof,^4,5,6 James Allan,¹ Christine Harrison,¹ Josef Vormoor,¹ Arend von Stackelberg,⁴ and Cornelia Eckert^4,5

¹Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom; ²Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom; ³Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; ⁴Charité-Universitätsmedizin Berlin, Department of Paediatric Oncology/Haematology, Berlin, Germany; ⁵German Cancer Consortium (DKTK), Berlin, Germany; and ⁶German Cancer Research Center (DKFZ), Heidelberg, Germany